• LAST PRICE
    0.7322
  • TODAY'S CHANGE (%)
    Trending Down-0.0167 (-2.2299%)
  • Bid / Lots
    0.7350/ 4
  • Ask / Lots
    0.7800/ 21
  • Open / Previous Close
    0.7500 / 0.7489
  • Day Range
    Low 0.7300
    High 0.7800
  • 52 Week Range
    Low 0.5000
    High 4.1000
  • Volume
    11,170
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.7489
TimeVolumePHIO
09:50 ET15580.75
10:14 ET1000.73
10:33 ET15480.73
10:42 ET5000.7386
10:46 ET1000.7404
10:48 ET5000.740299
10:55 ET1000.7795
11:13 ET1000.7795
11:18 ET1000.7795
11:51 ET39680.755
12:09 ET1000.78
12:30 ET1000.78
12:38 ET1000.78
12:50 ET1000.78
01:03 ET1000.78
01:12 ET2030.7307
01:42 ET2000.7672
01:46 ET5000.76
02:24 ET2000.7322
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPHIO
Phio Pharmaceuticals Corp
4.1M
-0.2x
---
United StatesKRBP
Kiromic Biopharma Inc
4.1M
-0.1x
---
United StatesALZN
Alzamend Neuro Inc
4.0M
-0.3x
---
United StatesCYTO
Altamira Therapeutics Ltd
3.6M
-0.1x
---
United StatesNEXI
Neximmune Inc
4.3M
-0.1x
---
United StatesKZIA
Kazia Therapeutics Ltd
6.4M
-0.3x
---
As of 2024-05-30

Company Information

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Contact Information

Headquarters
11 APEX DRIVE, SUITE 300A, PMB 2006MARLBOROUGH, MA, United States 01752
Phone
508-767-3861
Fax
508-767-3862

Executives

Chairman of the Board, President, Chief Executive Officer
Robert Bitterman
Lead Independent Director
Robert Ferrara
Independent Director
Patricia Bradford
Independent Director
Geert Cauwenbergh
Independent Director
Jonathan Freeman

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$4.1M
Revenue (TTM)
$0.00
Shares Outstanding
5.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.41
EPS
$-3.71
Book Value
$2.06
P/E Ratio
-0.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.